Loading
A phase 2 trial of Nivolumab in hepatocellular carcinoma and metastatic cancer, run by TaiRx, Inc., now recruiting.
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT05257590 by TaiRx, Inc., with 95 participants planned, started 2022-05-23 and due to reach its primary completion in 2026-12-31. Interventions recorded: Nivolumab Injection [Opdivo], CVM-1118. Conditions listed: Hepatocellular Carcinoma, Advanced Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares TaiRx, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Advanced hepatocellular carcinoma (BCLC C), Nivolumab, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma, Metastatic cancer (cancer that has spread).
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/